Clinical trial
Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
NCT02726789 is registered in ClinicalTrials.gov with Replicor Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
- Lead sponsor
- Replicor Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2012
- Completion date
- December 31, 2016
- Enrollment
- 5 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.